SCHEMBL19503528

SCHEMBL19503528

CNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-]

nearest known ligand 0.89

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 19/20 0.89
▸ BCL2L1 Q07817 2/20 0.84
▸ MCL1 Q07820 2/20 0.84
▸ BCL2L2 Q92843 2/20 0.84
▸ NSD2 O96028 1/20 0.84
▸ ADORA3 P0DMS8 1/20 0.84
▸ CYP2C9 P11712 1/20 0.84
▸ ADRA2C P18825 1/20 0.84
▸ SLC6A2 P23975 1/20 0.84
▸ BID P55957 1/20 0.84
▸ SLC6A3 Q01959 1/20 0.84
▸ ASPH Q12797 1/20 0.84
▸ BAD Q92934 1/20 0.84
▸ NSD1 Q96L73 1/20 0.84
▸ NSD3 Q9BZ95 1/20 0.84
▸ TMEM97 Q5BJF2 1/20 0.83
▸ HDAC1 Q13547 1/20 0.82
▸ HDAC6 Q9UBN7 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19503607 0.95 BCL2 (0.81) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL29657433 0.94 BCL2 (1.00) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL1701622 0.94 BCL2 (1.00) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL19839471 0.94 BCL2 (1.00) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL29376504 0.94 BCL2 (1.00) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL16160641 0.94 BCL2 (0.91) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL1699820 0.94 BCL2 (0.88) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL30313906 0.94 BCL2 (0.88) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL28621314 0.94 BCL2 (0.88) BCL2BCL2L1MCL1BCL2L2NSD2
SCHEMBL1702040 0.94 BCL2 (1.00) BCL2BCL2L1MCL1BCL2L2NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319316-B2 Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof BIOVENTURES, LLC (US) 2022-05-03 — — US disclosed
US-20200331905-A1 Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof BIOVENTURES, LLC 2020-10-22 — — US disclosed
US-10807977-B2 Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof BIOVENTURES, LLC (US) 2020-10-20 — — US disclosed
US-20190135801-A1 COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF BIOVENTURES, LLC 2019-05-09 — — US disclosed
US-20190054097-A1 COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF BIOVENTURES, LLC 2019-02-21 — — US disclosed
WO-2017184995-A1 COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF BIOVENTURES, LLC (US) 2017-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331905-A1 Compounds That Induce Degradation of Anti-Apoptotic BCL-2 Family Proteins and the Uses Thereof BCL2, BAX, BCL2L1 BCL2 1/4885BCL2L1 3/4885MCL1 8/4885
US-20190135801-A1 COMPOUNDS THAT INDUCE DEGRADATION OF ANTI-APOPTOTIC BCL-2 FAMILY PROTEINS AND THE USES THEREOF BCL2, BAX, BCL2L1 BCL2 1/4885BCL2L1 3/4885MCL1 8/4885
US-11319316-B2 Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof BCL2, BAX, BCL2L1 BCL2 1/4885BCL2L1 3/4885MCL1 8/4885
US-10807977-B2 Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof BCL2, BAX, BCL2L1 BCL2 1/4885BCL2L1 3/4885MCL1 8/4885
US-20190054097-A1 COMPOSITIONS TARGETING SENESCENT CELLS AND THE USES THEREOF TP53, MCL1, LIMS1 BCL2 52/4885BCL2L1 190/4885MCL1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback